Clinical Trial Update: Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating how long extended-release aspirin suppresses platelets in patients with diabetes and cardiovascular disease; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Diabetes Mellitus

Drugs mentioned

• Extended-release aspirin (acetylsalicylic acid)

Snippet

Sponsor: New Haven Pharmaceuticals, Inc. | Conditions: Cardiovascular Disease | Phase 1 | Status: COMPLETED